Huada Gene adheres to the concept of inclusive precision prevention and control to help innovation technology sink

Recently, the Nature magazine announced the Nature INDEX 2022 Tables of 2022, and the Chinese statement is now bright, with 16753.86 "SHARE" (ranking indicator) second place. Among the top 10 life scientific industrial institutions worldwide, Huada, as the only Chinese industrial institution, was on the list, and the remaining nine institutions were from the United States, Switzerland and the United Kingdom.

Adhering to the vision of "genetic technology benefit humanity", Huada is committed to protecting the community of human health and health under the guidance of the outline of innovation technology and the benefit of people's livelihood. As a listed company of Huada, Huada Gene has always attached great importance to the research and development of innovation and technology. Over the years, it has adhered to high investment in molecular testing upstream experimental technologies and information technology, as well as high investment in applications such as health, tumor prevention and control, and prevention and control of diseases in infection. Most diseases are harmful to humans.

Industry insiders pointed out that because of a lot of companies that attach importance to innovation as China ’s genes, the birth of China's life science industry is booming. It is expected that more companies will lead China's life science industry to peak in the future.

Adhere to the concept of precision prevention and control of inclusive

In the past 10 years, Huada Gene has closely combined scientific and technological innovation with the benefit of the people's livelihood, and brought the "out of reach" genetic technology into ordinary people's homes. Huada Gene believes that genetic technology is the forefront of research in the scientific community today, but the highest ideal of scientific research is inclusive. Washinga Gene must adhere to the concept of public health and inclusiveness in public health and inclusiveness. Empower the public health of inclusive.

For Huada genes, there are two main key to inclusive: First, with independent controllable technologies, by reducing sequencing costs and making the price of genetic testing more "close to the people", this is also a major The reason; the second is the people's livelihood project with large samples, bringing gene technology to the people of the people, reducing the birth of children with genetic patients, early detection of tumors and infection cases, and effectively reducing the probability of onset from preventing prevention and reducing family burden.

Untitled pre -producing testing is one of the most mature business applications at the current genetic testing, and it is also the earliest genetic testing technology used in Huada Gene to clinical detection. Based on the technical advantages of domestic independent sequencing platforms and the scale effect of detection, the company took the lead in expanding gene health screening The people's livelihood projects used in large samples promote the comprehensive prevention and control of birth defects. In July 2019, the company helped Hebei Province to launch a free screening project of unparalleled prenatal and deaf genes in pregnant women in the province, becoming the first region in the country with full coverage of the province in the country. In August 2022, Huada Gene officially announced that the company's non -invasive prenatal genetic testing sample sample sample samples were officially announced at the 17th International Genomics Conference.

Since the new crown epidemic, the concept of "prevention is greater than governance" and "prevents governance first" has been popularized in the whole society, and it is highly consistent with the vision of the company's technology inclusiveness. The pattern solves the effectiveness of the disease prevention and control of the disease. In addition to the prevention and control of birth defects, Huada gene also provides a comprehensive solution for "pre -, sieve, diagnosis, and supervision" that runs through the whole life cycle of cancer.

As of the end of 2021, the screening business of Huada gene cervical cancer has covered more than 130 cities or regions of 31 provinces across the country, providing HPV testing for nearly 6.2 million people. Through timely clinical diagnosis or intervention, ; Recently launched a 100 -dollar liver cancer genetic testing product to provide scientific and effective and inclusive solutions for the screening of liver cancer; in the field of innovative business exploration of "prevention -oriented", the company launched the Multi -centered projects in the country serve the era of aging population.

At the same time, in order to open up the "last mile" of early screening of tumors, the company launched a "two cancer" intelligent screening vehicles, which is committed to improving the early treatment rate of "two cancers" in county rural women. The company launched intestinal cancer testing products Hua Changkang R non -invasive bowel cancer gene test can provide intestinal cancer positive diagnosis and negative insurance services, create a one -stop closed -loop solution for bowel cancer, and actively explore and promote the screening of adults. model.

Decoding innovation to sink the technology to the grassroots level

Gene sequencing has played a great role in monitoring and traceability of new crown viruses. As a result, this technology has quickly become the focus of the market. With the continuous reduction of sequencing costs, such as fertility, tumor, pathogenic microorganisms, etc. The maturity and penetration rate improvement, gene sequencing, especially high -throughput sequencing markets, are expected to continue to maintain high -speed growth.

According to the "China Gene Sequencing Industry Market Prospective and Investment Strategic Planning Report" prediction, the global gene sequencing market size is expected to reach US $ 34.1 billion by 2025, and the compound growth rate of compound growth will remain at 18%from 2020 to 2025.

Huada Gene always adheres to the use of independent technology and cutting -edge science and technology to actively empower the medical service system and scientific research system in various places. Through the construction of joint laboratories, building a precision medical platform, and technical exchanges, it will help scientific research and medical services. Essence The company always adheres to the principles of science, effectiveness, and availability in the process of transformation of new scientific research achievements. It can ensure that scientific conclusions can truly reflect its value and be more extensive when transforming into technology and product services. The application of crowds makes more people benefit.

Focusing on the development of conventional business development, the layout of overseas channels has stabilized as the epidemic has stabilized, and research institutions and investors are concerned about the development strategies of conventional businesses in the post -epidemic era in the era of Huada.

Huada Gene stated that in 2022 and the next three years, the company will continue to increase forward -looking product deployment and product qualification declaration, including overseas product qualification reserves, support the company's existing major business areas, and will carry out concretely in multiple business areas. Strategic layout.

In the field of fertility health, Huada Gene promotes the detection of prenatal screening forward, the development and promotion of product development before and early pregnancy, and increase the first -level prevention of monomatological diseases, such as thalassemia and scalability carrier screening Market expansion; promoting the gradual transformation of the traditional foundation of non -invasive genetic testing business towards the upgraded version of the non -invasive non -invasive cause, which has begun to achieve results; the coverage of accelerated neonatal deaf gene screening has improved, and the newborn gene screening track is quickly cut into the newborn gene screening track Essence

In terms of tumor prevention and control, Huada genes on the basis of existing bowel cancer, liver cancer testing, and two cancer (cervical cancer, breast cancer) screening products, increase product development and application conversion, clinical performance verification of early screening of multiple cancers, and verification Investment in terms of domestic and foreign qualification declarations; all types of “pre -, sieve, diagnosis, and monitoring” closed -loop products are constructed around multiple types of tumors.

In terms of infection prevention and control, Huada genes establishes the diagnosis and medication needs of sensing diseases and pathogenia, and establish a test from community screening to hospitals' difficulties in infection. The control of high, middle and low -throughput products in control. At the same time, the company will also pay attention to the disease -related diseases of genetic cardiovascular and cerebrovascular, and help the practical application in the field of chronic disease management through precise testing technology.

In terms of international business development, Huada Gene, as the leader of the industry, has achieved outstanding business expansion worldwide with the frontal advantages of technology and channels. Circles have enabled many businesses such as fertility, tumor prevention and control, infection prevention and control, overseas, and achieve channel transformation.

Huada Gene has closely followed up global science and technology progress. After years of adherence to the deepening of the life technology industry, it has gradually achieved leading development in various application fields. At present, Huada Gene is a few companies covering the entire application field of gene sequencing, and focusing on the development direction of the industry and market demand, the step -by -order layout of multiple platforms and multi -products has formed a number of businesses for underlying technology applications. The situation of power. In the future, with the deepening of the perception of precision medicine in academia and the public, cross -group testing and diagnosis in the direction of fertility, tumors, infections, etc. will obtain faster promotion and popularity in clinical practice. Leading companies will continue to lead the industry's healthy and sustainable development, and further shape the industry's good ecology. Text/Wu Lei

Daily Economic News

- END -